2022 SITC Press Releases

11/11/22 – FDA Approves Tremelimumab in Combination with Durvalumab and Platinum-Based Chemotherapy for Metastatic Non-Small Cell Lung Cancer 

11/10/22 – FDA Approves Cemiplimab-rwlc in Combination with Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer 

11/3/22 – SITC to Hold Press Briefing on Nine Abstracts to be Presented at 37th Annual Meeting 

11/2/22 – SITC 2022 Late-Breaking Abstracts Announced 

10/26/22 – FDA Approves Teclistamab-cqyv for Relapsed or Refractory Multiple Myeloma 

10/25/22 – FDA Approves Tremelimumab in Combination with Durvalumab for Unresectable Hepatocellular Carcinoma 

10/7/22 – The Society for Immunotherapy of Cancer (SITC) Publishes a Checklist to Maximize the Benefit to Patients for Clinical Trials in Immuno-oncology 

9/8/22 – Oncology News Burst from FDA: durvalumab

8/30/22– SITC Announces Annual Award Recipients

8/11/22- SITC Forward Fund Announces 2022 Fellowships and Tech Award Recipients


7/12/2022 - SITC to Convene Oncology Leaders to Address the Crisis in Clinical Research at Virtual Summit

5/18/22 – SITC Announces Keynote Speaker Dr. Padmanee Sharma and Keynote Panel Honoring the Work of Dr. Zelig Esshar at its 37th Annual Meeting

5/10/22 – SITC’s Steven A. Rosenberg Scholars Award: $150,000 in Funding for an Emerging Leader in Immuno-Oncology

4/26/22 – Cancer Researchers to Rock Buddy Guy’s Legends for One Night Only

3/9/22 – Oncology News Burst from FDA: Nivolumab

1/13/22 – SITC to Offer Program for Emerging Leaders in Cancer Immunotherapy Focused on Accelerating Professional Development and Innovative Collaborations